In a filing, Takeda Pharmaceutical Co ADR revealed its President, Plasma-Derived Ther Giles Richard Platford acquired Company’s shares for reported $0.28 million on Aug 23 ’24. In the deal valued at $14.94 per share,19,073 shares were bought.
Morgan Stanley upgraded its Takeda Pharmaceutical Co ADR [TAK] rating to an Overweight from a an Equal-weight in a research note published recently. A number of analysts have revised their coverage, including BofA Securities’s analysts, who increased its forecast for the stock in mid March from “a Neutral” to “a Buy”. Cowen also remained covering TAK and has increased its forecast on July 19, 2022 with a “an Outperform” recommendation from previously “Market perform” rating. Morgan Stanley revised its rating on October 07, 2021. It rated TAK as “an Equal-weight” which previously was an “an Overweight”.
Price Performance Review of TAK
On Friday, Takeda Pharmaceutical Co ADR [NYSE:TAK] saw its stock jump 0.63% to $14.36. Over the last five days, the stock has lost -6.27%. Takeda Pharmaceutical Co ADR shares have risen nearly 8.46% since the year began. Nevertheless, the stocks have risen 8.13% over the past one year. While a 52-week high of $15.43 was reached on 05/05/25, a 52-week low of $12.57 was recorded on 01/23/25. SMA at 50 days reached $14.89, while 200 days put it at $14.14.
Levels Of Support And Resistance For TAK Stock
The 24-hour chart illustrates a support level at 14.27, which if violated will result in even more drops to 14.19. On the upside, there is a resistance level at 14.51. A further resistance level may holdings at 14.66. The Relative Strength Index (RSI) on the 14-day chart is 40.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.51, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 88.02%. Stochastics %K at 24.78% indicates the stock is a holding.
